OTCMKTS:IPSEY Ipsen (IPSEY) Stock Price, News & Analysis $30.73 0.00 (0.00%) As of 01/31/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartDividendHeadlinesShort Interest About Ipsen Stock (OTCMKTS:IPSEY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ipsen alerts:Sign Up Key Stats Today's Range$30.73▼$30.7350-Day Range$27.28▼$32.0452-Week Range$27.00▼$34.06Volume426 shsAverage Volume649 shsMarket Capitalization$10.30 billionP/E RatioN/ADividend Yield0.68%Price TargetN/AConsensus RatingN/A Company OverviewIpsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.Read More… Receive IPSEY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter. Email Address IPSEY Stock News HeadlinesFormer exec at drugmaker Ipsen sentenced to prison for insider tradingJanuary 30 at 5:59 PM | reuters.comJefferies Reaffirms Their Hold Rating on Ipsen (0MH6)January 30 at 7:56 AM | markets.businessinsider.comBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin Skimming allows you to “skim” cash into your account thanks to 2025’s surging Bitcoin market.February 2, 2025 | Brownstone Research (Ad)Barclays Remains a Hold on Ipsen (0MH6)January 21, 2025 | markets.businessinsider.comIpsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncologyDecember 3, 2024 | markets.businessinsider.comIpsen And Biomunex Reach Licensing Agreement For MAIT Cell Engager In Immuno-OncologyDecember 3, 2024 | markets.businessinsider.comBylvay® (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | uk.finance.yahoo.comIpsen Pharma: Bylvay (odevixibat) data shows sustained improvement in severe itch and serum bile acid levels in patients with PFIC and ALGSNovember 18, 2024 | finanznachrichten.deSee More Headlines IPSEY Stock Analysis - Frequently Asked Questions How have IPSEY shares performed this year? Ipsen's stock was trading at $28.97 at the start of the year. Since then, IPSEY stock has increased by 6.1% and is now trading at $30.73. View the best growth stocks for 2025 here. How do I buy shares of Ipsen? Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today2/02/2025Next Earnings (Estimated)2/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolOTCMKTS:IPSEY CUSIPN/A CIKN/A Webwww.ipsen.com Phone(315) 833-5000Fax33-01-58-33-50-01Employees5,300Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.14 Quick Ratio0.98 Sales & Book Value Annual Sales$3.58 billion Price / Sales2.88 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares335,260,000Free FloatN/AMarket Cap$10.30 billion OptionableNot Optionable Beta0.93 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free Report This page (OTCMKTS:IPSEY) was last updated on 2/2/2025 by MarketBeat.com Staff From Our PartnersStunning Trump Manhattan Project Now UnderwayJust as I predicted, President Trump announced his #1 move during his first 100 days... His allies are call...Banyan Hill Publishing | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ipsen S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ipsen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.